Clinical Trial

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Through regular monitoring of viral load, liver function and immune cell activity, the long-term efficacy of Adefovir in controlling HBV is precisely evaluated. By employing a dual mechanism of "antiviral action plus immune activation", it offers a novel therapeutic option for achieving clinical cure in chronic hepatitis B.
Trial Details
NCT Number NCT07307586
Lead Sponsor Zhigang Ren
Conditions Chronic Hepatitis B, Azvudine
Enrollment 120 participants
Start Date 2025-09-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-29